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Abstract: Hormone therapy is well established for treating patients with prostate cancer and 
remains the mainstay of the treatment of metastatic and locally advanced disease, this article 
reviews the rationale for its use, its different forms, and complications and controversies still 
surrounding some of its modalities. Availability of long-acting synthetic luteinizing hormone-
releasing hormone (LHRH) agonists revolutionized the hormonal treatment of prostate cancer, 
and helped to avoid the emotional and psychological effects related to surgical castration. The 
depot formula has gained wide acceptance from both patients and physicians. This review 
emphasizes the newer, long-acting formula, leuprorelin (leuprolide acetate), especially the 
6-month formula, its advantage over over shorter-acting depot products, and its potential to 
become a standard of care for patients eligible for androgen deprivation therapy.
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Introduction
In the post prostate-speciﬁ  c antigen (PSA) era, screening for prostate cancer has not 
only led to a stage migration, but also to a higher incidence of the disease. Such a 
trend has decreased the incidence of metastatic disease at diagnosis and paralleled the 
decrease in the mortality rate from prostate cancer.
The incidence of metastatic disease was only 1.6% of patients enrolled in the 
Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), diagnosed 
between 1998 and 2003 (Ryan et al 2006). On the other hand the population failing 
the initial treatment is increasing, and 40% of the patients treated with curative intent 
eventually end up with PSA recurrence (Ward and Moul 2005), raising the question 
of whether there is any evidence that aggressive intervention in these patients may 
result in cure.
Because many patients with T3 disease or local lymph node metastases progress to 
distant metastases, some authors recommended that the concept of advanced prostate 
cancer should also include stages C and D1 (Moul 2004) (T3, T4, and any T N1).
Today, in addition to its well-established role in treating patient with metastatic 
disease, androgen deprivation therapy (ADT) is sometimes used to treat patients with 
biochemical failure even without evidence of local or systemic recurrence. This therapy 
is also used as an adjunct to radiation for high risk localized disease.
The treatment of locally advanced and metastatic prostate cancer is only pal-
liative, and most patients who respond initially to ADT ultimately evolve towards 
hormone refractory disease within 2 years, and at this stage, unfortunately, alterna-
tive modalities such as chemotherapy become of limited value, with a survival of 
only 18–24 months.Therapeutics and Clinical Risk Management 2008:4(2) 514
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This inevitable evolution led to new strategies being 
explored for delaying progression to androgen independence, 
which may involve targeting of anti-apoptotic factors, use 
of chemotherapy at the time of androgen ablation, or block-
age or down-regulation of androgen receptor (AR) activity 
(Petrylak 2005). Among those novel options is a broad 
range of promising strategies such as targeting signal trans-
duction pathways, cell cycle regulation and differentiation, 
and angiogenesis (Cavarretta et al 2005).
Prostate cancer: a hormone 
sensitive malignancy
The prostate – testis relationship has been known since the 
18th century when John Hunter (Androutsos 1998) demon-
strated in 1786 that castration in young male animals pre-
vented further growth of the prostate, whereas in the adult 
it caused atrophy. Hunter also observed that aging eunuchs 
never suffered from symptoms of a hypertrophied prostate 
(Home 1811).
The second half of the 19th century marked a growing 
interest in orchiectomy for the treatment of prostatic hyper-
plasia, particularly urinary retention. Symptomatic improve-
ment in over half of patients with an enlarged prostate treated 
with castration was reported by William White in 1895 and 
1904 (White 1895, 1904).
The development of prostate cancer requires the presence 
of a prostate gland and a source of androgens. It has been 
shown that androgens produced elsewhere can be activated in 
the prostatic tissue, as prostate cancer never occurs in those 
with testicular feminization syndrome and in patients with 
5-alfa reductase deﬁ  ciency (Newling 1996).
Before 1940s there was no effective treatment for 
advanced prostate cancer. In 1939 Charles Huggins, aware 
of androgens sensitivity of the prostate gland, proposed 
orchiectomy to control prostate cancer. He demonstrated 
that castration decreased the height of prostatic epithelial 
cells in normal prostatic tissue, and that testosterone admin-
istration stimulated the secretory activity of dogs’ prostatic 
cells (Huggins and Clark 1940); furthermore, he proved that 
castration produced clinical pain relief and a stabilization 
or regression of metastatic osseous lesions (Huggins et al 
1941) and reduction in acid phosphatase level (Huggins and 
Hodges 1941). Huggins soon realized, however, that the same 
results could be achieved by the less drastic procedure of 
the administration of female sex hormones to neutralize the 
effect of androgens produced by the testicles. Consequently, 
in 1941 he began to inject his patients with the hormones 
stilbestrol and hexestrol.
Other forms of castration have been developed, such as 
the technique of radio-orchiectomy (Keyes and Ferguson 
1936), consisting of irradiation of the testis in patients with 
advanced prostate cancer.
Ninety to 95% of the androgens are produced by the testes 
and only 5%–10% by the adrenals. These small amounts of 
androgens continue to support tumor growth.
The involvement of the adrenal gland in hormonal con-
trol of prostate malignancies was supported by reports of an 
increase in the urinary concentration of 17-keto-steroids in 
patients after castration (Satterthwaite et al 1941; Schröder 
2002). The recognition of the role of adrenal androgens in 
prostate cancer led to the development of the therapeutic 
strategy known as combined androgen blockade.
The early form of this approach combined orchiectomy 
and bilateral adrenalectomy. The ﬁ  rst procedure in a patient 
with prostate cancer was carried out by Huggins and William 
Wallace Scott in 1945 (Huggins and Scott 1945), who dem-
onstrated a clinical beneﬁ  t of such procedure in men with 
disease recurrence after orchiectomy.
The initial success of hormonal therapy led on the one 
hand to less interest in radical surgical and radiation treat-
ment, even for localized disease. On the other hand, it led to 
a tendency to remove sound organs with vital functions such 
as adrenals (adrenalectomy) and the pituitary gland (surgical 
ablation [Silverberg and Britt 1979]) and external irradiation 
(Murphy and Schwippert 1951) of the pituitary gland, as well 
as the implantation of radioactive material (Fergusson 1957), 
in hope of completely suppressing androgens and therefore 
curing or slowing disease progression.
Schally and associates (1971) puriﬁ  ed the decapeptide 
gonadotropin-releasing hormone, referred to as LHRH. The 
availability of long-acting synthetic luteinizing hormone-
releasing hormone (LHRH) agonists in the 1980s revolu-
tionized the hormonal treatment of prostate cancer, enabling 
many men to avoid the emotional and psychological effects 
of surgical castration (McLeod 2003).
Anti-androgens block testosterone action in target tissues 
by interfering with testosterone or dihydrotesterone (DHT) 
binding to the steroid-binding domain of the androgen recep-
tor. Steroidal anti-androgens, such as cyproterone acetate, 
also have some ability to block luteinizing hormone (LH) 
secretion, and are therefore associated with many of the 
sexual effects seen with LHRH agonists (See 2003).
By contrast, the non-steroidal anti-androgens have been 
associated with a far more beneﬁ  cial sexual side effect pro-
ﬁ  le. Non-steroidal anti-androgens, such as ﬂ  utamide, were 
ﬁ  rst used in the mid 1970s (Sogani et al 1975) and steroidal Therapeutics and Clinical Risk Management 2008:4(2) 515
Leuprorelin depot injection for prostatic cancer
anti-androgens such as cyproterone acetate were approved 
for use in the 1980s (Jacobi 1983).
The gonadotropin-releasing hormone (GnRH) antago-
nists represent the newest class of agents introduced for the 
hormonal treatment of prostate cancer. The advantages of 
GnRH antagonists are that they do not cause the initial surge 
in testosterone associated with LHRH agonists and they rapidly 
achieve castrate androgen levels.
In clinical trials, monotherapy with abarelix was shown 
to achieve medical castration more rapidly than leuprorelin 
(leuprolide acetate) alone or in combination with bicaluta-
mide and without an early surge in testosterone (Trachtenberg 
et al 2002).
Physiology: hypothalamus – 
pituitary – testis axis
LHRH, also known as GnRH, is secreted in a pulsatile fashion by 
the hypothalamus. The increase in LHRH stimulates the anterior 
pituitary to secrete LH and follicle-stimulating hormone into the 
systemic circulation (Denmeade and Isaacs 2004). LH stimulates 
the Leydig cells of the testes to secrete testosterone.
Testosterone is converted into a more potent compound, 
DHT. Conversion occurs in the cytoplasm of prostatic cells 
by the enzyme 5-alfa reductase. In addition to testosterone, 
adrenal androgens may be converted to DHT (Sandow et al 
1988). In the cytosol, DHT binds to the androgen receptor 
and crosses into the nucleus. The activated androgen recep-
tor binds to speciﬁ  c DNA sequences that inﬂ  uence gene 
expression, stimulate the synthesis of speciﬁ  c proteins such 
as PSA, and trigger cell proliferation.
In the normal prostate, androgen is the major growth fac-
tor through two mechanisms: on the one hand, it stimulates 
cellular proliferation of prostatic epithelial cells; on the other, 
it blocks the potentially high apoptotic rate of epithelial cells. 
The net balance determines the overall number of prostate 
cells (Isaacs 1984, 1994).
Testosterone-lowering strategies 
(Table 1)
The ﬁ  rst method of permanent castration was bilateral orchi-
ectomy, and the ﬁ  rst reversible method was diethylstilbestrol 
(DES) (Byar and Corle 1988).
Therapeutic approaches to interrupt the production and/or 
block the action of testosterone include:
(1) Suppression of testosterone via surgical removal of the 
testes or use of estrogens;
Table 1 Methods to interrupt the production of and/or block the action of testosterone
Methods Action Side effects
Orchiectomy Surgical suppression of testicular male hormones leading 
to immediate drop in testosterone (Iversen 1998)
Limitations include its irreversible nature causing 
erectile dysfunction, occasional post-operative 
complications, and associated psychological factors 
(Cassileth 1989)
Estrogens The negative feedback on the hypothalamus afforded by 
estrogen. Suppression of LHRH release and subsequent 
decrease not only of LH but also of FSH (Brawer 2001)
Cardiovascular complications. gynecomastia is a 
common complaint
LHRH agonists Over-stimulation of the LHRH receptors, followed by 
subsequent drop due to the loss the pulsatile secre-
tion pattern (LSG 1984); the net effect is a reduction of 
testosterone to castration levels within 2–4 weeks
Testosterone surge and potential for clinical ﬂ  are
LHRH antagonists Inhibition of LHRH and subsequent rapid time to 
testosterone suppression with a higher rate of medical 
castration (Debruyne 2004)
-   Safety of abarelix is comparable to that of LHRH 
agonists with or without anti-androgen
- Cost
- Increased liver enzymes
Anti-androgens Block the binding of DHT to the androgen receptors in 
the prostate (Iversen 2001)
Gynecomastia, breast pain
Diarrhea,visual disturbances
Inhibitors of alfa-reductase Inhibit 5-alfa reductase conversion of testosterone to 
DHT in the prostate
Gynecomastia, breast pain, anemia
Ketoconazole In high dose is able to produce castrate levels of andro-
gens (both testicular and adrenal) within 4–8 h of the 
ﬁ  rst dose (Lowe 1990)
Gastrointestinal disturbances and suppression of 
cortisol production which resulted in subsequent 
Addisonian crisis and sudden death (Pont 1987)
Abbreviations: DHT, dihydrotesterone; LH, luteinizing hormone; LHRH, luteinizing hormone-releasing hormone; FSH, follicle-stimulating hormone.Therapeutics and Clinical Risk Management 2008:4(2) 516
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(2) LHRH agonists to down-regulate the pituitary and prevent 
release of LH or by using LHRH antagonists to directly 
suppress LH release;
(3) Inhibition of 5-alfa reductase conversion of testosterone 
to DHT in the prostate;
(4) Blocking the binding of DHT to the androgen receptors 
in the prostate.
These strategies can be used individually or in various 
combinations.
In 1983, ketoconazole in high dose was identiﬁ  ed as 
able to produce castrate levels of androgens within 4–8 h of 
the ﬁ  rst dose (Trachtenberg and Point 1983), and represents 
an alternative treatment where urgent androgen ablation is 
required (Lowe and Bamberger 1990).
Biological effects of androgen 
deprivation
Anterior pituitary – testis axis
With longer-term administration, a resetting of the anterior 
pituitary receptor occurs, with subsequent reduction in LH 
along with follicle-stimulating hormone (FSH) release, 
resulting in achievement of castrate levels of testosterone 
(Conn et al 1984). Chronic exposure to LHRH ultimately 
suppressed testosterone by desensitizing pituitary cells 
through down-regulation of the LHRH receptors (Van 
Loenen et al 2002).
Castration, the time-honored frontline treatment for meta-
static prostate cancer, was previously deﬁ  ned by induction 
of a serum testosterone level of  50 ng/mL (Coppage and 
Cooner 1965; Young and Kent 1968). Recent literature rede-
ﬁ  nes this upper limit as  20 ng/mL (Oefelein et al 2000).
Prostate cell level
Effects of androgen deprivation include apoptosis of both 
cancer cells and benign prostatic epithelium (Denmead et al 
1996; Buttyan et al 2000). One of the earliest events, occur-
ring prior to the initiation of epithelial apoptosis, is degen-
eration of the prostatic vasculature. This has been observed 
in animal models as well as in the human prostate (Franck-
Lissbrant et al 1998; Shabisgh et al 1999). A recent study 
has shown that in patients on complete androgen blockade 
therapy (CAB), there were morphological changes within 
the prostatic tissues as early as 7 days after initiating ADT, 
similar to the response to castration. These changes induce 
signiﬁ  cant involution within prostatic tissues over 7–28 
days, but allow the persistence of some viable tumor cells 
capable of proliferation (Mercader et al 2007). This event is 
mediated at least in part by decreased expression of vascular 
endothelial growth factor (VEGF), an androgen-regulated 
gene, in the prostatic epithelium and stroma (Burchardt et al 
2000). This phenomenon of apoptosis does not affect basal 
cells which remain intact. A high percentage of androgen-
independent cancers appear to maintain expression of the 
AR gene, but many have genetic alterations that change 
receptor activity. Altered expression of AR co-activators 
may occur in recurrent cancer, and AR mutations may 
occur in as many as 40%–50% of such cancers. Proteins 
involved in cell survival and resistance to apoptosis are 
over-expressed in androgen-independent prostate cancer 
cells or tumors (Peehl 2001).
Indication of ADT in prostate 
cancer
Today, in addition to its well-established role in treating 
patients with metastatic disease, ADT is sometimes used to 
treat patients with biochemical failure even without evidence 
of local or systemic recurrence. This therapy is also used 
as an adjunct in patients undergoing radiation for high-risk 
localized disease.
Controversies around hormonal therapy
Several controversies still surround the modalities of this 
therapy (Table 2):
•  Monotherapy or CAB?
•  Early versus delayed?
•  Continuous or intermittent?
•  Adjuvant or neoadjuvant?
•  Secondary manipulation after failure of initial hormonal 
therapy?
•  Hormone after PSA recurrence?
•  Hormone for localized prostate cancer.
•  Role of anti-androgens alone?
•  Role of anti-5AR + antiandrogens?
LHRH agonists ﬂ  are issue
During the initial 1–2 weeks the LHRH receptor is overstimu-
lated, initially resulting in testosterone surge and potential 
for clinical ﬂ  are. There is a delay in testosterone reduction 
and a surge in testosterone and dihydro-testerone as well as 
elevation of PSA. Symptomatic ﬂ  are may result. The impact 
of the increase in FSH is only now undergoing evaluation, but 
this too may have an untoward effect on prostatic carcinoma. 
The ﬂ  are phenomenon may be life threatening if an LHRH 
agonist is administered to men with high-volume metastatic 
disease. The clinical consequence of the ﬂ  are is prevented 
by pretreatment with an anti-androgen, which inhibits the Therapeutics and Clinical Risk Management 2008:4(2) 517
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(Continued )
Table 2 Controversies around hormonal therapy for prostate cancer
HT modality Argument for Argument against
Early vs delayed HT The appropriate time to initiate hormonal therapy for prostate 
cancer remains a matter of debate.
Two recent studies provide convincing clinical evidence support-
ing the early treatment of advanced prostate cancer (Kirk 2000; 
Messing 1999).
The randomized trial reported by the Medical Research Council 
(MRC) has shown more rapid local and distant disease progression 
in the deferred treatment group, increase in serious complications, 
such as pathologic fractures, spinal cord compression, and there was 
clear survival advantages associated with early hormone therapy for 
high risk malignancies (MRC 1997).
Also in Eastern Cooperative Oncology Group (ECOG)/SWOG 
Stage D1 (N+) study (Messing 1999),  the survival in the delayed 
therapy and immediate therapy arms was 65% and 85%, respectively.
Arguments for early hormonal therapy are countered, 
however, by a number of factors, including:
•    The long natural history for most men of rising 
PSA levels before clinical metastases and death
•   No randomized controlled clinical trials to conﬁ  rm 
the survival advantage or to document the long-
term effects of such therapy.
The side effects of hormone therapy, particularly for 
younger men
•   Cost of hormone treatment, particularly if over a 
long period of time.
Studer et al (2006) has shown that there is no beneﬁ  t 
in early versus delayed treatment in patients with clini-
cally localized prostate cancer not suitable for radical 
therapy.
CAB From 1980 to 1991, approximately 36 prospective, random-
ized studies were performed, 27 of them being reasonably well 
designed with at least 1 year of therapy. Of these, only 3 showed 
a statistically signiﬁ  cant improvement in overall survival (Craw-
ford 1989; Denis 1998).
Although the overall beneﬁ  t of MAB may be small, some patients 
will likely show a more substantial improvement in survival com-
pared with androgen suppression alone. Should remain a reason-
able option when discussing treatments for metastatic prostate 
cancer (Messing 1999).
A recent Japanese study showed that ﬁ  rst-line combination 
LHRH-agonists therapy with bicalutamide 80 mg in patients with 
advanced prostate cancer offered signiﬁ  cant beneﬁ  ts over LHRH-
A alone, with respect to TTTF, TTP, although the difference in the 
interim overall survival was not statistically signiﬁ  cant (Usami 
2007).
The lack of beneﬁ  t in any of the other 24 studies led 
to much debate about the overall beneﬁ  t of MAB in 
men with metastatic disease.
The survival beneﬁ  t for MAB of only 3% has led many 
experts to believe that the beneﬁ  t is overshadowed by 
the therapy cost and side effects (Chodak 2004, 2005).
This option became feasible only when medical castration 
became available. Advantages include reduction of side effects 
from therapy such as the physiological changes associated with 
castration, reduction of cost, and potentially delayed emergence 
of hormone refractoriness as evidenced by laboratory data 
(Sandford 1984).
Controversy remains as to which patients might bene-
ﬁ  t the most from intermittent hormonal therapy, when 
to start hormonal therapy, how long to treat before 
stopping, and when to restart subsequent cycles.
Intermittent 
hormone 
therapy
The most recent evidence is the mature experience of phase II 
trial from Ottawa group. Intermittent AS therapy was initiated 
in prostate-cancer patients to delay hormone resistance and 
minimize potential side effects of androgen-deprivation therapy 
(Malone 2007). Intermittent AS has also the potential to reduce 
side effects, including recovery of hemoglobin level, return of 
sexual function and absence of weight gain at the end of the 
study period (Malone 2005). Its use in D1 and D2 
prostate cancer patients appears to be safe and feasible. Off 
treatment periods are  40% and contribute to patients’ quality 
of life (Miller 2007).
Anti-androgen 
alone
Monotherapy with bicalutamide 150 mg once daily provides a 
survival outcome that is not signiﬁ  cantly different to that of cas-
tration in men with locally advanced, non-metastatic disease, while 
conferring signiﬁ  cant advantages for sexual interest and physical 
capacity (Boccon-Gibod 1997; Pavone-Macaluso 1994).
The most common side effects of non-steroidal anti-
androgen monotherapy are gynecomastia and male 
breast pain. These events occur more frequently than 
with castration alone (McLeod 1997; Migliari 1999).Therapeutics and Clinical Risk Management 2008:4(2) 518
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Table 2 (Continued)
HT modality Argument for Argument against
The administration of low-dose ﬂ  utamide (125 mg) was clinically 
effective in treating PSA recurrence after deﬁ  nitive treatments for 
prostate cancer, and was well tolerated (Barqawi 2003).
Anti-androgen 
and Inhibition 
of 5-alfa 
reductase
The combination of ﬁ  nasteride and ﬂ  utamide showed a moder-
ate efﬁ  cacy in patients with PSA-only recurrence after deﬁ  nitive 
therapy. The efﬁ  cacy appears to be greater in patients who can 
achieve a PSA nadir of 0.1 ng/mL or less after the start of treat-
ment (Barqawi 2003).
This combination is also regarded as a potency-sparing therapy.
It is inevitable that the overwhelming majority of men treated 
with pharmacologic or surgical castration will develop disease 
progression due to development and propagation of androgen-
independent prostate cancer cells. Although it offers modest 
activity, it represents an alternative to early use of chemotherapy 
in patients with androgen independent disease.
Although the side effects are low, combined ﬁ  naste-
ride and ﬂ  utamide therapy signiﬁ  cantly lowers hemo-
globin and haematocrit levels in men with advanced 
prostate cancer (Ornstein 1999).
Secondary HT The strategy can be summarized as follow either the adjunc-
tion second-line non-steroidal anti-androgens or its withdrawal 
in case of initial CAB, the use of inhibitors of adrenal androgen 
production such as ketoconazole (Scholz 2005).
The future direction would involve the development of molecules 
that effectively inhibit androgen receptor through changes in 
the ligand binding complex activating conformational changes or 
co-factor recruitment (Small 2006).
Preclinical evidence supports the hypothesis that FSH signaling 
contributes to progression of AIPC. Patients on LHRH agonists 
have modestly reduced but detectable FSH levels, whereas 
patients treated with orchiectomy have signiﬁ  cantly elevated 
FSH levels. Abarelix suppresses FSH more effectively than LHRH 
agonists when used as front-line hormonal therapy (Beer 2004).
Longevity following progression has historically been 
short, with a reported median of 6–9 months, given 
the lack of efﬁ  cacious treatment options (Taneja 2003).
With the development of potentially efﬁ  cacious 
chemotherapeutic regimens, particularly taxane-based 
chemotherapies, secondary manipulation may delay 
therapy (Petrylak 2007).
PSA-only 
Recurence 
after Radical 
Prostatectomy
Moul et al in a large retrospective multi-center study, found that 
delayed hormonal therapy in high-risk disease (GS   7 and PSA 
DT   12 months) was associated with an approximately 2-fold 
increased risk of metastasis (Moul 2004).
Whoever this study has the limitations of retrospective studies and 
requires validation to reach a meaningful result (Freedland 2005).
Retrospective study, revealed that patients with PSA 
recurrence who did not undergo hormonal depriva-
tion therapy had a median actuarial time to metastasis 
of 8 years after PSA rise, only 34% had apparent 
metastases (Pound 1999).
HT provides no beneﬁ  t or might even harm men with 
low-risk/local disease (Leibovitz 2001).
Androgen 
deprivation as 
monotheraphy 
for local-
ized prostate 
cancer
Primary ADT has long been the treatment of choice for localized 
and locally advanced prostate cancer in Japan and more evidence 
of its efﬁ  cacy is accumulating. This trend is also on the rise in 
clinical practice in the USA (Akaza 2006).
More evidence has been accumulating that progression of 
prostate cancer was retarded by primary hormone therapy in 
men with localized or locally advanced prostate cancer (Akaza 
et al 2006).
Some authors described that triple androgen blockade (LHRH 
agonist+anti-androgens) therapy followed by ﬁ  nasteride main-
tenance appears to be a promising for management of localized 
prostate cancer (Labrie 2002), and long-term and continuous 
CAB offers the possibility of long-term control or possible cure 
of localized prostate cancer (Janoff 2005).
ADT resulted in poor control of localized prostate 
cancer. In particular, younger patients and those with 
Gleason   6 cancers were at higher risk of treatment 
failure.
And the toxicity, principally in the form of bone frac-
tures, was high (Janoff 2005).
Androgen deprivation as a primary therapy for local-
ized prostate cancer provided modest disease control, 
but toxicity was high. Younger men with tumors of 
Gleason score  6 had a higher risk of biochemical 
progression (Kirk 2006).
(Continued )Therapeutics and Clinical Risk Management 2008:4(2) 519
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Table 2 (Continued)
HT modality Argument for Argument against
Adjuvant HT NAS can reduce the number of tumor clonogens prior to radiation, 
thus increasing the tumor control probability. Also, NAS may sensi-
tize tumor cells to radiation if cell kill by both modalities follows a 
common pathway.   The timing and sequence of NAS and radiation 
are important, with radiation being most effective if given at the 
point of maximal tumor regression (Zietman 2000; Hall 2000).
Pilepich showed that the incidence of local failure at 10 years was 
23% in the adjuvant arm, compared with 38% in the radiation 
alone The 10-year rate of distant metastases was 24% in the adju-
vant arm, compared with 39% in the control arm (p   0.0001) 
and concluded that adjuvant androgen suppression reduces dis-
ease progression and improves survival in patients with unfavor-
able-risk, high-grade prostate cancer treated with radiotherapy 
(Pilepich 2005).
The 5-year bRFS rate for patients with unfavorable 
tumors who received radiation doses of 72 Gy or 
greater vs less than 72 Gy was 75% and 41 %, respec-
tively; thus the beneﬁ  t might not be due to adding 
hormone to higher radiation dose (Lyons 2000). There 
appeared to be little if any beneﬁ  t of adding neoadju-
vant AS before high intensity focused ultrasound for 
men with presumed organ-conﬁ  ned prostate cancer 
(Uchida 2006).
Neo-adjuvant and adjuvant HT before radical 
prostatectomy showed a signiﬁ  cant reduction in 
the positive surgical margin rate, from 23% to 12% 
(p = 0.01) for patients who received 3 vs 8 months 
of neoadjuvant AST, but no cancer control outcomes 
(Gleave 2001).   A recent study to evaluate NHT 
prior to radical prostatectomy for high-risk prostate 
cancer, showed that biochemical failure was frequent 
after this combined treatment, even in a pT0 ca 
which questions the use of modality in this category 
of patients (Tabata 2006).
Abbreviations: ADT, androgen deprivation therapy;   AIPC, androgen-independent prostate cancer;   AS, androgen suppression; DHT, dihydrotesterone;  CAB, complete androgen 
blockade;  HT, hormone therapy; LH, luteinizing hormone; LHRH, luteinizing hormone-releasing hormone; FSH, follicle-stimulating hormone; MAB, maximum androgen blockade; NAS, 
neoadjuvant androgen suppression; NHT, neoadjuvant hormonal therapy; PSA, prostate-speciﬁ  c antigen; TTTF,. time-to-treatment failure; TTP, time-to-disease progression.
stimulatory effect of the testosterone surge at the level of 
the androgen receptor (Thompson 2001).
Patients with symptomatic advanced prostate cancer such 
as those with signiﬁ  cant obstructive voiding symptoms merit 
a ﬂ  are-free induction of hormonal therapy, as do patients 
with signiﬁ  cant back pain and early neurologic sequelae: 
both urinary retention and paraplegia are side effects to be 
avoided.
Optimal blockade is achieved by pretreatment with an 
appropriate agent (eg, anti-androgen), or for the patient in 
whom maximum blockade is desirable immediately, consid-
eration could be given to the use of ketoconazole, which dra-
matically reduces testosterone in only a matter of hours.
Failure to achieve castrate level
A small but potentially important subgroup of men on depot 
LHRH agonist therapy fail to achieve or maintain a castrate 
level of testosterone (Oefeien and Comum 2000), a ﬁ  nding 
that supports the need for monitoring testicular response 
during LHRH agonist therapy (Morote et al 2006).
Cost of treatment
For an individual patient the cost of LHRH agonist treat-
ment surpassed the cost of surgery at less than 4.2–5.3 
months, and for combined androgen blockade (LHRH 
agonists and non-steroidal anti-androgens) at less than 
2.7–3.4 months (Mariani et al 2001). Except for patients 
with short anticipated survival, current medical androgen 
suppressive treatment options are more costly than bilateral 
orchiectomy.
For men who accept it, bilateral orchiectomy is likely to 
be the most cost-effective androgen suppression strategy. 
Combined androgen blockade is the least economically 
attractive option, yielding small health beneﬁ  ts at high rela-
tive costs (Bayoumi et al 2000).
Complications of hormonal therapy
The common side effects of hormonal manipulation are hot 
ﬂ  ushes. Changes in the hormonal balance induced by hor-
monal manipulation in men with prostate cancer can increase 
the likelihood of gynecomastia, which usually resolves spon-
taneously after cessation of hormonal manipulation during 
the ﬁ  rst year (Kumar et al 2005).
Men with prostate cancer who are initiating ADT have a 
5- to 10-fold increased loss of bone density at multiple skel-
etal sites compared with either healthy controls or men with 
prostate cancer who are not on ADT. Bone loss is maximal 
in the ﬁ  rst year after initiation of ADT, suggesting initiation Therapeutics and Clinical Risk Management 2008:4(2) 520
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of early preventive therapy (Greenspan et al 2005; Shahinian 
et al 2005). Hormone therapy does not appear to cause 
clinically signiﬁ  cant changes in depression among men with 
locally advanced prostate cancer. However, fatigue increased 
signiﬁ  cantly over the study period (Koupparis et al 2004).
The current data suggest that men with prostate cancer 
who are receiving long-term ADT are at risk for developing 
insulin resistance, hyperglycemia (Basaria et al 2006), and 
the occurrence of metabolic syndrome (Braga-Basari et al 
2006), thus leading to an increased risk of cardiovascular 
complications.
Compared with normal men, total and free testosterone 
levels during treatment were 1.8-fold and 2.3-fold higher in 
obese men. These differences may contribute to the associa-
tion between obesity and increased prostate cancer mortality 
(Smith 2007), loss of sexual desire, erectile dysfunction, 
and anemia.
Pituitary adenomas (Massoud et al 2006) together with 
subcutaneous granulomas (Whitaker et al 2002) mimick-
ing metastatic metastatic nodules have also been described 
with ADT.
Leuprorelin
Chemical composition and different 
formulas
Natural LHRH was ﬁ  rst isolated and identiﬁ  ed in 1971 
(Schally et al 1971). Leuprorelin (leuprolide acetate) was 
ﬁ  rst synthesized in 1974 by Takeda Chemical Industries, 
Japan (Fujino et al 1974).
Leuprorelin is a synthetic non-peptide analogue of 
naturally occurring porcine LHRH. It has a longer half-life 
than natural LHRH due to its enhanced binding afﬁ  nity and 
increased resistance to peptidase degradation. At least two 
alterations in chemical structure serve to enhance the biologic 
activity of GnRH. These alterations include substitution of 
a D-amino acid for the glycine molecule at position 6 and 
deletion of the glycine molecule at position 10, and usually 
replacement by an N-ethylamide group (Monahan et al 1973). 
Leuprorelin is 80 times more potent than natural LHRH 
(Chrisp and Sorkin 1991).
Leuprorelin is orally inactive and originally was generally 
given subcutaneously or intramuscularly; leuprorelin 1 mg 
was given by daily injection. However, a depot formulation 
was soon developed to enable convenient subcutaneous or 
intramuscular injection at 1-month intervals. The clinical 
beneﬁ  t of treating prostate cancer with LHRH analogues 
was reported from 1982 (Tolis et al 1982).
Leuprorelin was initially administered subcutaneously to 
men with metastatic prostate cancer as a daily 1-mg injec-
tion, starting in 1985.
The monthly depot was ﬁ  rst launched in Europe in France 
in April 1989, and now is well established as the leading 
LHRH analogue. Since the publication of earlier reviews 
(eg, Chrisp and Sorkin 1991), new formulations have also 
been developed to maximize ﬂ  exibility and convenience of 
administration for both doctor and patient.
Microsphere technology enables leuprorelin to be given 
as a depot formulation. Leuprorelin microspheres range in 
mean diameter between 10 and 20 mm for the 1-month depot 
and between 10 and 30 mm for the 3-month depot. Clini-
cally, this means that leuprorelin can be given as a liquid 
injection through a ﬁ  ne-gauge needle using conventional 
injection techniques.
Sustained-release parenteral depot formulations, in which 
the hydrophilic leuprorelin is entrapped in biodegradable 
highly lipophilic synthetic polymer microspheres, have 
been developed to avoid daily injections (Shariﬁ   et al 1997; 
Periti et al 2002). In-situ forming drug delivery systems are 
prepared by dissolving a drug and a biodegradable polymer 
(poly (D, L-lactide-co-glycolide; PLGA) in a biocompatible 
organic solvent. In clinical studies of prostatic cancer, use 
of the depot formulation has effectively reduced the dose 
required to as low as one-eighth of that needed for adminis-
tration by daily injection (Togushi 1992).
Three- and 4-month formulations of leuprorelin were 
approved by the FDA for this indication in 2002 and 2003. 
Within a few years of its introduction, the 3-month depot 
accounted for 45% of the LHRH agonist market, and the 
4-month formulation accounted for 40% of the market in 
its ﬁ  rst year.
The development of depot forms of the LHRH agonists 
provided a well accepted approach to effective castration. 
Current formulations of 3- or 4-month (or longer) prepara-
tions are widely utilized; the most recent addition is the 6-
month formula. Other beneﬁ  ts of the LHRH agonists include 
no cardiovascular toxicity and the fact that the “castration” 
is reversible.
Subcutaneous implants have been developed; the implant 
is designed to be removed after 12 months, and then another 
implant can be inserted for continued therapy.
Implants require a surgical incision and have greater 
injection site reactions; however, patients avoid multiple 
injections. The leuprorelin implant (Viadur®) effectively 
suppressed testosterone concentrations to less than the cas-
trate threshold and maintained that suppression throughout Therapeutics and Clinical Risk Management 2008:4(2) 521
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the study period (Fowler et al 2000a). Some authors claimed 
testosterone suppression to the castrate range of 100% 
(Fowler et al 2000b; Mark 2003).
Histrelin acetate 50 mg subdermal implant (Vantas®) 
also seems to achieve similar results in men with advanced 
prostatic cancer. The hydrogel implant provided consistent 
delivery of histrelin over 1 year. Testosterone suppression 
was maintained throughout the 52 weeks after implantation 
in more than 99% of patients. No testosterone or LH surge 
was observed with re-implantation. PSA, a secondary end 
point for effectiveness, was also suppressed signiﬁ  cantly 
from baseline (Schlegel 2006).
Pharmacokinetics
After injection of the 1-month depot formulation of leu-
prorelin 3.75 mg, peak serum levels are achieved within 
1 hour, followed by a rapid fall over the next 24 hours. A 
dose-dependent plateau is maintained over at least 5 weeks, 
representing a constant rate of release of leuprorelin from 
the copolymer (Mazzei et al 1990).
As with the 1-month injection, the 3-month injec-
tion (11.25 mg), results in an initial rise in serum levels 
of leuprorelin, followed by continuous linear release. A 
serum level of about 200–287 pg/mL is maintained over 
at least 3 months (Wechsel et al 1996) (equivalent to that 
achieved with a 1-month dose of 3.75 mg after repeated 
injections).
Mechanism of action
Leuprorelin acts as a potent inhibitor of gonadotropin 
secretion when given continuously in therapeutic doses. 
Animal and human studies indicate that after an initial 
stimulation as with other LHRH analogues (3–4 days), 
chronic administration of leuprorelin suppresses testicular 
and ovarian steroidogenesis. In humans, administration of 
leuprorelin initially increases circulating levels of LH and 
FSH, leading to a transient increase in levels of the gonadal 
steroids. However, continuous administration of leuprorelin 
decreases levels of LH and FSH, and subsequently reduces 
testosterone. These decreases occur within 2–4 weeks after 
initiation of treatment.
To obtain optimal therapeutic effect against androgen-
dependent tumor cells, serum testosterone levels must be 
reduced to castrate levels (=50 ng/dL) (Fergusson 1957). 
This level can be achieved by a 1-month depot injection of 
3.75 mg leuprorelin (Whitaker et al 2002) or by at 3-month 
depot injection of 11.25 mg (Khan and O’Brien 1998), or 
other new depot formulations.
GnRH agonist administration was shown by Redding 
and Schally to reduce the growth of prostate tumors in 
rats (Redding and Schally 1983). Early clinical studies 
in metastatic or advanced prostate cancer established the 
efﬁ  cacy of daily s.c. injection of leuprorelin (1–20 mg) in 
suppressing testosterone levels, delaying tumor progres-
sion, and alleviating symptoms of locally advanced and 
metastatic prostate cancer (Trachtenberg 1983; Yamanak 
et al 1984). This effect is reversible upon discontinuation 
of drug therapy and this therapeutic approach has now 
replaced surgical castration.
Comparative studies on other androgen 
suppression modalities (Table 3): 
comparison of different depot formulas
The US Food and Drug Administration (FDA) has empha-
sized the importance of testosterone in prostate cancer 
therapy by utilizing decrease in testosterone associated with 
ADT as a surrogate endpoint for prostate cancer treatment 
(Brawerr 2001). It is intriguing that the agency uses testos-
terone and not PSA level in this regard. Therapies directed 
at treating prostate cancer on a hormonal basis need only to 
demonstrate achievement of castrate levels of testosterone 
for approval by the FDA.
Another requirement of GnRH agonists and other endo-
crine therapies for prostate cancer is the ability to maintain 
castration levels of testosterone while on long-term therapy. 
Different formulas have been proven to be meet those criteria 
(Table 4). Selecting the best product may be based on: patient 
comfort, side effects or injection-site reactions, ease of use 
such as patient preparation, time, and stafﬁ  ng required for 
administration.
Six-month formulation of leuprorelin 
depot (Eligard® 45-mg)
Six-month leuprorelin acetate (Eligard® 45-mg; Atrix Labo-
ratories) is a new formulation for the palliative treatment of 
advanced prostate cancer.
In recent study conducted by Crawford et al (2006), the 6-
month depot formulation of leuprorelin 45-mg (Eligard®) was 
evaluated clinically in a 12-month, open-label, multicenter 
study in patients with prostate cancer. The mean time required 
to reach castrate T levels ( 50 ng/dL) was 21 days, 99% 
had 12-month testosterone (T) levels  50 ng/dL, and 88% 
patients had T levels  20 ng/dL. Mean PSA levels decreased 
from 39.8 ± 21.5 ng/mL at baseline to 1.2 ± 0.3 ng/mL at 
12 months.Therapeutics and Clinical Risk Management 2008:4(2) 522
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The 6-month formula of leuprorelin is the new addition 
which has a number of advantages over shorter-acting depot 
products, while reducing the need to schedule actual treat-
ment time to only twice yearly.
Patients who may beneﬁ  t from include those who:
• Are stable and well controlled on palliative therapy
• Travel for extended periods of time
• Have difﬁ  culty getting to the physician’s ofﬁ  ce (eg, due to 
limited mobility or long travel distance)
• Receive an LHRH agonist as neoadjuvant therapy.
Moreover, the change in Medicare reimbursement 
(Painter 2005) for injections to “budget neutral” removes 
any incentive for favoring a formulation that is given more 
often over one that is given every 6 months. Of the urolo-
gists polled, 77% said that they were likely to use a 6-month 
depot rather than the shorter treatment regimens currently 
available. This novel delivery system allows for a low-
volume injection, with very small changes in volume with 
increased dosage.
The Atrigel® Delivery System is composed of a 
biodegradable polymer (DL-lactide-coglycolide) dissolved 
in a biocompatible liquid solvent (N-methyl-2-pyrrolidone, 
or NMP). Because of its larger volume, leuprorelin depot is 
typically injected into the buttocks, necessitating the use of 
a treatment room. Patients receiving Lupron® Depot may 
experience pain at the injection site lasting up to 2 days, large 
abscesses, and bruising. However, there was no statistically 
signiﬁ  cant difference in pain experienced on injection of 
goserelin and leuprorelin when patients were unaware of 
needle size (Montgomery et al 2005).
Conclusion
After seven decades, ADT has stood the test of time and 
gained its place as the mainstay of treatment for advanced 
and metastatic prostate cancer. It has relieved the symptoms 
and prolonged the life of many patients. Its discovery and 
reﬁ  nement have brought two Nobel prizes to the medical 
community, ﬁ  rst with the seminal work of Charles Higgins on 
the inﬂ  uence of the endocrine system on the development of 
a human malignancy in 1966, and then in 1977 with Andrew 
Schally’s work on the hypothalamic hormones.
ADT went through several steps and reﬁ  nement pro-
cesses to reach its current status. In the 1940s the only 
option available was the irreversible castration through 
orchiectomy or the administration of female hormones, 
today the options are myriad.
The availability of long-acting synthetic LHRH ago-
nists in the 1980s revolutionized the hormonal treatment of 
Table 3 Leuprorelin: comparative studies to other androgen suppression modalities
  Testosterone lowering/   Comment  Reference
 blocking  method
Leuprorelin  Orchietomy  Equivalent, orchiectomy, cost  (Parmar 1985; Cassileth 1989;
    effective but associated   Iversen 1998; McLeod 2003)
    with psychological complications
  Estrogens (DES 3 mg)   Equivalent, less cardiovascular   (LSG 1984)
  vs 1 mg/day leuprorelin  side effects with leuprorelin.
  Other LHRH agonists  No meaningful difference among   (Seidenfeld 2000)
    the various approved GnRH agonists.
  LHRH antagonists (aberalix)  Short time to testosterone  (McLeod 2001; Debruyne 2004)
   suppression.
    No testosterone surge with aberalix.
    Safety is comparable to that of
    LHRH agonists with or without anti-androgens.
Abbreviation: LHRH, luteinizing hormone-releasing hormone.
Table 4 Leuprorelin formulas and testosterone suppression
Leuprorelin formula  Injection volume (mL)  Testosterone castrate level  Authors
    50 ng/dL  20 ng/dL 
7.5 mg monthly  0.250  100.0%  97.5%  Perez-Mareno 2002
22.5 (3 month)  0.375  98%    Berges 2006
   98%  84%  Chu  2002
30 mg (4 month)  0.500  96%    Shariﬁ   1998
45.0 mg (6 month)  0.375  99%  88%  Crawford 2006Therapeutics and Clinical Risk Management 2008:4(2) 523
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prostate cancer, enabling many men to avoid the emotional 
and psychological effects of surgical castration. The depot 
formulas have gained wide acceptance from both patients 
and physicians.
The 6-month formula of leuprorelin represents a new 
addition to the armentarium that has a number of advantages 
over shorter-acting depot products. It suppresses the testoster-
one to the castrate level in the majority of patients completing 
treatment without any breakthrough responses.
Compared with a 3-month depot, the 6-month depot 
is associated with two rather than four opportunities for 
patients to lose therapeutic effect if they delay their injection 
beyond the formulation’s normal duration, thus improving 
the patient’s compliance to therapy and quality of life.
The limited number of injections reduces the anxiety 
due to physician’s ofﬁ  ce visit and fear of pain; injection 
takes minimal time which is the most desirable option from 
the nursing standpoint. The drug is well tolerated while 
maintaining a side effect proﬁ  le comparable to other prod-
ucts in its class.
These advantages coupled with the recent change to 
Medicare legislation will make long-duration formula-
tion an attractive option for physicians, and will certainly 
tip the balance in favor of this option in treating prostate 
cancer patients fulﬁ  lling the criteria for receiving such 
products.
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